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The Association of Albuminuria With Tubular Reabsorption of Uric
Acid: Results From a General Population Cohort
Lieneke Scheven, MD; Michel M. Joosten, PhD; Paul E. de Jong, MD, PhD; Stephan J. L. Bakker, MD, PhD; Ron T. Gansevoort, MD, PhD;
For the PREVEND study group
Background-—Elevated albuminuria as well as an increased serum uric acid concentration is associated with poor cardiovascular
outcome. We questioned whether these 2 variables (albuminuria and serum uric concentration) may be interrelated via tubular uric
acid reabsorption.
Methods and Results-—Included were 7688 participants of the PREVEND Study, an observational, general population-based cohort
study. Linear regression analyses were used to test associations of baseline albuminuria with baseline serum uric acid
concentration and tubular uric acid reabsorption (calculated as [100fractional uric acid excretion]%). Cox regression analyses
were used to study the association of baseline serum uric acid and albuminuria with incident cardiovascular morbidity and
mortality. In cross-sectional analyses, albuminuria was associated positively with serum uric acid concentration, both crude and
after adjustment for potential confounders (both P<0.001). Albuminuria was found to be associated positively with tubular uric acid
reabsorption, again both crude and after adjustment for potential confounders (both P<0.001). In longitudinal analyses during a
median follow-up of 10.5 years, 702 cardiovascular events occurred. After adjusting for cardiovascular risk factors, both
albuminuria and serum uric acid were associated with incident cardiovascular events (Hazard Ratios 1.09 [1.03 to 1.17], P=0.01
and 1.19 [1.09 to 1.30], P<0.001, respectively). A signiﬁcant interaction between these variables was present (P<0.001),
consistent with high serum uric acid being less predictive for cardiovascular morbidity and mortality in the presence of high
albuminuria and vice versa.
Conclusions-—Albuminuria is strongly associated with tubular uric acid reabsorption, and consequently with serum uric acid
concentration. This phenomenon may explain in part why albuminuria is associated with cardiovascular outcome. ( J Am Heart
Assoc. 2014;3:e000613 doi: 10.1161/JAHA.113.000613)
Key Words: albuminuria • cardiovascular outcome • tubular reabsorption • uric acid
U ric acid is the ﬁnal oxidation product of purinecatabolism in humans. For decades it has been
hypothesized that the antioxidant properties of uric acid
might be protective against aging, oxidative stress, and
oxidative cell injury.1 However, recent epidemiological and
clinical evidences suggest that hyperuricemia might be a risk
factor for cardiovascular disease, where enhanced oxidative
stress plays an important pathophysiological role.1,2 The
apparent paradox between protective and toxic effects is
supported by clinical evidence that antioxidant compounds
may become pro-oxidant compounds in certain situations,
particularly when they are present in blood at supranormal
levels.1 In line, several epidemiological studies have reported
an association between elevated serum uric acid concentra-
tion and increased albuminuria.3–7 In general, this association
has been explained as serum uric acid causing endothelial
dysfunction, which is reﬂected by an increase in albuminuria.8
Uric acid is the end product of purine metabolism. The
mechanism of renal uric acid handling is complex. In blood,
urate is only minimally bound to proteins. Therefore, almost
100% is freely ﬁltered at the glomerulus into the renal
tubule.9,10 In the proximal tubule, almost complete reabsorpi-
tion, secretion and postesecretory reabsorption take place
sequentially. These processes are mediated by various urate
transporters at the apical and basolateral membrane of
proximal epithelial tubular cells.10 In conert they cause
healthy individuals to have reabsorption of urate relatively
constant at about 95%.10
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Like serum uric acid albuminuria also has been found to
be associated with increased risk for cardiovascular disease.
The amount of albumin that is lost in urine is the result of
the amount ﬁltered by the glomerulus and the amount
that escapes degradation or reabsorption by the proximal
tubule. Interestingly, recent studies have shown that prox-
imal epithelial tubular cells that are exposed to albumin
differentially up- and downregulate genes encoding for
membrane transporters.11–13 Others have shown that non-
albumin compounds found in the urine of proteinuric
patients, such as plasmin, inﬂuence the activity of membrane
transporters.14
Given these data we questioned whether albuminuria may
increase serum uric acid by inﬂuencing the activity of tubular
transport mechanisms. If such an interaction between albu-
minuria and serum uric acid concentration were to exist, it
may be anticipated that the associations of albuminuria and
serum uric acid with cardiovascular outcome will show an
interaction, ie, in subjects with higher albuminuria the
association of serum uric acid with cardiovascular outcome
is less strong.
We investigated these hypotheses using data from a large-
scale, observational cohort study in which data are available
on serum and urine uric acid concentration, as well as
albuminuria and cardiovascular outcome.
Patients and Methods
Study Design and Population
This study was conducted using data obtained in subjects who
participate in the Prevention of REnal and Vascular ENd-stage
Disease (PREVEND) study, which started in 1997. This
prospective cohort study investigates the natural course of
albuminuria and its relation to renal and cardiovascular
disease. Details of the study protocol have been published
elsewhere.15,16 In summary, all inhabitants of the city of
Groningen aged 28 to 75 years were sent a questionnaire on
demographics, disease history, smoking habits, use of
medication, and a vial to collect a ﬁrst-morning-void urine
sample. Of these subjects, 40 856 responded (47.8%). From
these subjects, the PREVEND cohort was selected with the
aim to create a cohort enriched for subjects with higher
albuminuria. After the exclusion of patients with type 1
diabetes mellitus (deﬁned as requiring the use of insulin) and
pregnant females (deﬁned by self-report), all subjects with a
urinary albumin concentration of >10 mg/L (7768) were
invited, of which 6000 participated. Furthermore, a randomly
selected control group with a urinary albumin concentration of
<10 mg/L (3394) was invited, of which 2592 participated.
These 8592 subjects constitute the actual PREVEND cohort
and were studied in more detail.
For the current study, participants were excluded with
missing data on serum or urine uric acid concentration
(N=210 and 54, respectively), serum or urine creatinine
concentration (N=34 and 33, respectively), urinary albumin
excretion (N=2), and participants who were using drugs
inﬂuencing uric acid metabolism (diuretics, allopurinol, and
benzpromaron, N=349). Furthermore, participants with outlier
values for serum uric acid (N=18) and tubular reabsorption
(N=6), and assumed errors in 24-hour urine collection were
excluded (N=198), leaving 7688 subjects for the present
study. The PREVEND study was approved by the medical
ethics committee of our institution and conducted in accor-
dance with the International Conference of Harmonization
Good Clinical Practice Guidelines and adheres to the ethical
principles that have their origin in the Declaration of Helsinki.
Measurements and Deﬁnitions
At the baseline visit participants ﬁlled in a questionnaire,
anthropometrical measurements were performed, and fasting
blood samples were taken. In addition, subjects collected
urine for 2 consecutive periods of 24 hours. Blood pressure
was measured in the supine position with an automatic device
(Dinamap XL Model 9300; Johnson-Johnson Medical). Blood
pressure is given as the mean of the last 2 recordings.
Concentrations of total cholesterol and plasma glucose
were measured using standard methods. Serum creatinine
was measured by dry chemistry (Eastman Kodak). Urinary
albumin concentration was measured by nephelometry with a
threshold of 2.3 mg/L and intra- and interassay coefﬁcients
of variation of 2.2% and 2.6%, respectively (BNII; Dade Behring
Diagnostic). Urinary albumin excretion is given as the mean of
the two 24-hour urine collections. Serum concentrations of
uric acid were measured with The Merck Mega clinical
chemistry analyzer with the uricase PAP (peroxidase-amin-
ophenazone) method, with an intra- and interassay coefﬁcient
of variation of 1.1% and 1.3%, respectively. Urinary uric acid
has been measured with the Merck Mega, with an intra-assay
and interassay coefﬁcient of variation 0.9% and 1.4%,
respectively.
Participants were considered to be smoking when, accord-
ing to the questionnaire, they had smoked in the year prior to
the baseline screening, and as using alcohol when, according
to the questionnaire, they had at least 1 to 4 drinks a month
in the year prior to the baseline screening. Cardiovascular
disease history was deﬁned as self-reported myocardial
infarction, percutaneous transluminal coronary angioplasty,
coronary artery bypass graft, or cerebrovascular accident.
Information on drug use in general was obtained from the
questionnaire, and on speciﬁc drug use from the Inter-Action
Data-Base (IADB), which comprises pharmacy-dispensing data
of community pharmacists located in the northern regions of
DOI: 10.1161/JAHA.113.000613 Journal of the American Heart Association 2















 at University of Groningen on January 8, 2015http://jaha.ahajournals.org/Downloaded from 
the Netherlands. These pharmacies provide the IADB data-
base a complete listing of patient-speciﬁc dispensed drugs.17
Hypertension was deﬁned as systolic blood pressure of
≥140 mm Hg, a diastolic blood pressure ≥90 mm Hg, or use
of antihypertensive medication according to self-report or to
pharmacy data. Hyperlipidemia was deﬁned as cholesterol
level >5.0 mmol/L in participants with a cardiovascular
disease history, a cholesterol level of >6.5 mmol/L when
such a history was absent or use of lipid-lowering drugs
according to self-report or to pharmacy data. Diabetes was
deﬁned as a fasting glucose level of >7.0 mmol/L, a
nonfasting glucose level of >11.1 mmol/L or use of antidi-
abetic medication according to self-report or to pharmacy
data. eGFR was estimated using the CKD-EPI equation and
body surface area (BSA) unadjusted.18 Body surface area was
calculated with the DuBois formula.19 Body mass index was
calculated as the ratio between weight and the square of
height (weight/height2), with obesity deﬁned as a body mass
index above 30 kg/m2.
Increased serum uric acid is deﬁned as a serum level of
>0.35 mmol/L for females and >0.45 mmol/L for males as
criteria for increased serum urate levels, similar to prior
reports.6,20 Uric acid excretion is deﬁned as 24-hour urinary
uric acid excretion. Fractional excretion of uric acid (%) was
calculated as ([urine uric acid]9[serum creatinine])/([urine
creatinine]9[serum uric acid]9100), and tubular uric acid
reabsorption (%) as 100(fractional uric acid excretion).
Outlier values were calculated for serum uric acid and
tubular reabsorption of uric acid, and were deﬁned as a value
that falls >1.5 times the interquartile range above the third
quartile or below the ﬁrst quartile.21 Errors in 24-hour urine
collections were deﬁned as the upper and lower 2.5% of the
difference between expected and actually measured 24-hour
urine volume. The expected 24-hour urine volume was
calculated by comparing creatinine clearance estimated by
the Cockgroft–Gault (CG) formula22 and actual creatinine
clearance (24-hour urine volume=(CG9[serum creatinine])/
[urinary creatinine]).
Cardiovascular Outcome
For cardiovascular outcome we used the incidence of the
combined outcome of cardiovascular morbidity and mortality.
Date and cause of death were obtained by record linkage with
the Dutch Central Bureau of Statistics. Information on
hospitalization for cardiovascular morbidity was obtained
from PRISMANT, the Dutch national registry of hospital
discharge diagnoses. All data were coded according to the
International Classiﬁcation of Diseases, ninth revision and the
classiﬁcation of interventions. For this study, cardiovascular
events were deﬁned according the Major Adverse Cardiovas-
cular Events (MACE) criteria as acute myocardial infarction
(ICD-code 410), acute and subacute ischaemic heart disease
(code 411), subarachnoid haemorrhage (code 430), intrace-
rebral haemorrhage (code 431), other intracranial haemor-
rhage (code 432), occlusion or stenosis of the precerebral
(code 433) or cerebral arteries (code 434), coronary artery
bypass grafting or percutaneous transluminal angioplasty, and
other vascular interventions such as percutaneous translumi-
nal angioplasty or bypass grafting of aorta peripheral vessels.
Statistical Analysis
Continuous data are reported as meansstandard deviation
(SD). In case of nonparametric data distribution medians with
interquartile range (IQR) are presented. Differences between
groups for continuous data were tested by Student t test or a
Mann-Whitney U test in case of nonparametric data distribu-
tion. Differences between groups for proportions were tested
with a chi-square test.
We ﬁrst performed linear regression analyses to test
associations of baseline albuminuria with baseline serum uric
acid or tubular uric acid reabsorption (cross-sectional analy-
ses), in univariable and in multivariable linear regression
analyses. Because urinary albumin excretion was not normally
distributed, this variable was logarithmically transformed to
meet the assumptions for linear regression analyses. These
regression analyses were performed crudely, as well as
adjusted for potential confounders that are known to
inﬂuence renal uric acid handling. For these analyses the
standardized beta coefﬁcients are given in the tables. These
refer to how many standard deviations a dependent variable
will change per standard deviation increase in the predictor
variable. Standardization of the coefﬁcient is usually done to
answer the question which of the independent variables has a
greater effect on the dependent variable in a multiple
regression analysis, when the variables are measured in
different units.
We next performed Cox-regression analyses to investigate
the association of albuminuria and serum uric acid with
cardiovascular morbidity and mortality during follow-up (lon-
gitudinal analyses). These analyses were performed univariate
as well as multivariate, adjusting for traditional cardiovascular
risk factors and potential confounders. In these models the
Hazard Ratio of continuous variables is expressed per
standard deviation of each variable, which allows direct
comparison of the strength of associations of individual
variables in the multivariate model. Furthermore, albuminuria
and serum uric acid were simultaneously entered in the
multivariable model. For Cox-regression analyses survival time
was deﬁned as the time between the date of urine collection
of the participant and the date of ﬁrst cardiovascular event or
January 1st, 2009 (end of follow-up). Subjects were censored
in case they died or moved to an unknown destination. In
DOI: 10.1161/JAHA.113.000613 Journal of the American Heart Association 3
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addition, it was investigated whether there was an interaction
between urinary albumin excretion and serum uric acid in
their association with cardiovascular morbidity and mortality
by adding the interaction term albuminuria9serum uric acid
to the full-adjusted model also containing both variables as
single terms.
Figures 1 and 2 were generated from results of linear
regression analyses. In the multivariable analysis the Hazard
Ratios are adjusted for age, gender, use of alcohol, BMI, eGFR,
and 24-hour urinary excretion of uric acid.
We performed several sensitivity analyses: we ﬁrst
repeated our analyses using design based regression analy-
ses, in which the fact that by design the PREVEND cohort is
enriched for subjects with higher albuminuria levels was taken
into account. The advantage is that results can be extrapo-
lated to the general population. Second, all the linear and Cox
regression analyses were performed using urinary albumin
concentration instead of 24-hour urinary albumin excretion, to
investigate whether incorrect 24-hour urine collection may
have inﬂuenced our results. Third, fractional sodium excretion
and hs-CRP were added to the multivariable model investi-
gating the associations of albuminuria with serum uric acid
concentration and tubular reabsorption of uric acid, because
these variables may be additional confounders in the asso-
ciation of albuminuria with serum uric acid concentration and
uric acid reabsorption.
All calculations were performed with SPSS version 18.0
software, and for all analyses a 2-sided P<0.05 was consid-
ered to indicate statistical signiﬁcance.
Results
The mean age of the 7688 study participants was
48.612.4 years. Approximately half of the participants were
of male gender. Mean serum uric acid was 0.300.08 mmol/
L. Mean urinary uric acid excretion was 1.70.7 mmol/24 h,
tubular uric acid reabsorption 95.72.1% and median urinary
Figure 1. Association between urinary albumin excretion and
tubular reabsorption of uric acid (mean and standard deviation),
with the population stratiﬁed in deciles of urinary albumin
excretion. Upper panel shows crude analyses; lower panel shows
the mean values adjusted for age, gender, use of alcohol, BMI,
eGFR, and 24-hour urinary excretion of uric acid. BMI indicates
body mass index; eGFR, estimated glomerular ﬁltration rate.
Figure 2. Association between urinary albumin excretion,
serum uric acid and relative risk for cardiovascular morbidity
and mortality. The upper panel shows crude Hazard Ratio’s, the
lower panel Hazard Ratio’s adjusted for cardiovascular risk factors
(age, gender, smoking, history of cardiovascular disease, obesity,
diabetes, hypertension, and hypercholesterolemia). Reference
category (HR=1) was chosen to be normal serum uric acid (<0.45
and <0.35 mmol/L in males and females, respectively) and
normoalbuminuria (<30 mg/24 h). CV indicates cardiovascular.
UAE, urinary albumin excretion.
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albumin excretion 9.3 (6.3 to 17.5) mg/24 h (Table 1). When
dividing the study population into subjects with normo- versus
increased albuminuria (>30 mg/24 h) it shows that 1124
participants had increased albuminuria (median urinary albu-
min excretion 60.8 [40.0 to 115.2] mg/24 h). These partic-
ipants are signiﬁcantly older, more often male, have a lower
eGFR, a higher serum uric acid concentration, and a higher
tubular uric acid reabsorption, while uric acid excretion was
similar (Table 1).
Baseline Associations Between Albuminuria,
Serum Uric Acid, Urinary Uric Acid Excretion, and
Tubular Reabsorption of Uric Acid
Albuminuria was associated positively with serum uric acid
concentration, both crude (model 1) and in models that
adjusted for potential confounders, including age and gender
(model 2), alcohol consumption, BMI, eGFR, and 24-hour
urinary uric acid excretion (model 3) and even after additional
adjustment for tubular reabsorption of uric acid (model 4)
(Table 2, all P<0.001), although a signiﬁcant attenuation of
effect was noted moving from the unadjusted to the fully
adjusted models.
When studied separately, albuminuria was signiﬁcantly
positively associated with tubular uric acid reabsorption, again
crude (model 1), as well as in models that adjusted for
potential confounders (models 2 through 4) (Table 3), the
higher albuminuria the higher tubular reabsorption of uric
acid. This association is visualized in Figure 1, with the study
population subdivided according to deciles of 24-hour albu-
minuria. The upper panel shows the crude association of
albuminuria with tubular uric acid reabsorption, and the lower
panel the association when adjusted for the covariates of the
multivariable regression model.
Associations of Albuminuria and Serum Uric Acid
with Cardiovascular Events During Follow-up
During a median follow-up of 10.5 years (0.03 to
11.3 years), 702 cardiovascular events occurred. In sepa-
Table 1. Baseline Characteristics of the Total Study Cohort and When Stratiﬁed According to Albuminuria Status
Total Cohort N=7688 UAE<30 mg/24 h N=6564 UAE>30 mg/24 h N=1124 P Value
Age, y 48.612.4 47.512.1 55.412.4 <0.001
Male gender, % 50.5 48.2 63.9 <0.001
Body mass index, kg/m2 26.04.2 25.74.0 27.94.8 <0.001
Obesity, % 14.9 12.8 26.9 <0.001
Smoking, % 38.1 37.7 40.3 0.10
Cardiovascular history, % 4.9 3.7 11.7 <0.001
Use of alcohol, % 75.0 75.5 71.8 0.01
Systolic blood pressure, mm Hg 128.419.9 125.918.1 142.923.4 <0.001
Diastolic blood pressure, mm Hg 73.89.7 72.79.1 79.911.0 <0.001
Antihypertensive medication, % 12.2 9.8 25.8 <0.001
Hypertension, % 31.0 25.7 62.0 <0.001
Serum glucose, mmol/L 4.81.1 4.80.9 5.41.9 <0.001
Glucose lowering medication, % 1.2 0.8 3.2 <0.001
Diabetes, % 3.3 2.1 9.9 <0.001
Serum cholesterol, mmol/L 5.61.1 5.61.1 5.91.1 <0.001
Lipid lowering medication, % 3.6 2.9 8.1 <0.001
Hyperlipidemia, % 27.2 24.9 40.5 <0.001
Serum creatinine, lmol/L 83.514.9 82.513.2 89.421.4 <0.001
Serum uric acid, mmol/L 0.300.08 0.300.07 0.330.08 <0.001
eGFR, mL/min 93.919.7 94.419.1 90.222.2 <0.001
Urinary albumin excretion, mg/24 h 9.3 (6.3 to 17.5) 8.2 (6.0 to 12.4) 60.8 (40.0 to 115.2) <0.001
Urinary uric acid excretion, mmol/24 h 1.70.7 1.70.7 1.70.8 0.91
Tubular reabsorption of uric acid, % 95.72.1 95.62.1 96.12.1 <0.001
eGFR indicates estimated glomerular ﬁltration rate.
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rate models serum uric acid and albuminuria were both
signiﬁcantly associated with cardiovascular morbidity and
mortality, both crude (Hazard Ratio [HR]) per standard
deviation (SD) 1.66 (1.55 to 1.77) and 1.53 (1.45 to 1.61),
respectively, both P<0.001), and after adjustment for
traditional cardiovascular risk factors (HR per SD 1.21
(1.10 to 1.32), P<0.001 and 1.11 (1.04 to 1.18), P=0.002,
respectively). When albuminuria and serum uric acid
concentration were entered simultaneously in the multivar-
iable adjusted model, both were signiﬁcantly associated with
cardiovascular outcome (standardized HR for albuminuria
1.09 [1.03 to 1.17], P=0.01 and for serum uric acid HR
1.19 [1.09 to 1.30], P<0.001) (Table 4). In the multivariate
model in which urinary albumin excretion and serum uric
acid concentration were simultaneously entered, it appeared
that there was a signiﬁcant interaction between these
variables (P<0.001), consistent with high serum uric acid
being less strongly associated with cardiovascular morbidity
and mortality in the presence of high albuminuria and vice
versa.
This association of baseline albuminuria and serum uric
acid concentration with cardiovascular outcome during follow-
up is visualized in Figure 2. Both higher albuminuria and
higher serum uric acid concentration are associated with a
higher relative risk for cardiovascular morbidity and mortality,
and a negative interaction is observed: in participants with
higher albuminuria the risk for cardiovascular morbidity and
mortality associated with a high serum uric acid concentration
is less strong, both crude (upper panel) as well as adjusted for
cardiovascular risk factors (lower panel).
Table 2. Association of Urinary Albumin Excretion With Serum Uric Acid (Dependent Variable), Both Crude and After Adjustment
for Confounders
Model 1 Model 2 Model 3 Model 4
St B P Value St B P Value St B P Value St B P Value
Ln albuminuria, mg/24 h 0.23 <0.001 0.12 <0.001 0.07 <0.001 0.03 0.001
Age, y 0.12 <0.001 0.12 <0.001 0.06 <0.001
Gender (female vs male) 0.51 <0.001 0.61 <0.001 0.36 <0.001
Use of alcohol (yes vs no) 0.09 <0.001 0.06 <0.001
BMI, kg/m2 0.38 <0.001 0.21 <0.001
eGFR, mL/min 0.29 <0.001 0.39 <0.001
Uric acid excretion, mmol/24 h 0.03 0.001 0.43 <0.001
Tubular reabsorption of uric acid, % 0.69 <0.001
BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate (CKD EPI-equation); ln, natural log-transformed. Standardized beta coefﬁcients refer to how many standard
deviations a dependent variable will change per standard deviation increase in the predictor variable. This allows a comparison which of the independent variables has a greater effect on
the dependent variable in multiple regression analysis, when the variables are measured in different units.
Table 3. Association of Urinary Albumin Excretion With Tubular Reabsorption of Uric Acid (Dependent Variable), Both Crude and
After Adjustment for Confounders
Model 1 Model 2 Model 3 Model 4
St B P Value St B P Value St B P Value St B P Value
Ln albuminuria, mg/24 h 0.12 <0.001 0.07 <0.001 0.03 0.01 0.06 <0.001
Age, y 0.03 0.004 0.03 0.03 0.08 <0.001
Gender (female vs male) 0.36 <0.001 0.31 <0.001 0.36 <0.001
Use of alcohol (yes vs no) 0.01 0.56 0.05 <0.001
BMI, kg/m2 0.25 <0.001 0.25 <0.001
eGFR, mL/min 0.11 <0.001 0.14 <0.001
Uric acid excretion, mmol/24 h 0.66 <0.001
BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate (CKD EPI-equation); Ln, natural log-transformed. Standardized beta coefﬁcients refer to how many standard
deviations a dependent variable will change per standard deviation increase in the predictor variable. This allows a comparison which of the independent variables has a greater effect on
the dependent variable in multiple regression analysis, when the variables are measured in different units.
DOI: 10.1161/JAHA.113.000613 Journal of the American Heart Association 6
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Sensitivity Analyses
Several sensitivity analyses were performed. First, when
design-based analyses were performed, accounting for the
fact the PREVEND cohort by design is enriched for partic-
ipants with higher levels of albuminuria, all aforementioned
analyses rendered essentially similar results (data not shown).
Second, we performed all analyses using urinary albumin
concentration instead of urinary albumin excretion. Again,
essentially similar results were obtained. Urinary albumin
concentration was signiﬁcantly associated with serum uric
acid concentration (Table 5) and tubular uric acid reabsorp-
tion (Table 6), both crude as well as in multivariable models.
Urinary albumin concentration and serum uric acid concen-
tration were both signiﬁcantly associated with cardiovascular
outcome in the multivariable model (HR 1.09 [1.03 to 1.18],
P=0.01 and HR 1.19 [1.09 to 1.30], P<0.001, respectively)
(Table 7), and the negative interaction between these 2
variables in their association with cardiovascular outcome
was again signiﬁcant (P<0.001). Third, because it has been
suggested that albuminuria and serum uric acid concentration
may also be dependent on sodium balance, serum albumin
and systemic inﬂammation, we added fractional sodium
excretion (mean 0.690.2%), serum albumin (mean
45.82.7 g/L), and high-sensitivity CRP (median 1.2, IQR
0.5 to 2.9 mg/L) to the multivariable model. This inﬂuenced
only slightly the association between albuminuria and serum
uric acid concentration (fully adjusted model standardized
beta 0.02, P=0.01, Table 8) and the association between
albuminuria and tubular reabsorption of uric acid (fully
adjusted model standardized beta 0.05, P<0.001, Table 9).
Discussion
In the present study, which uses data obtained in a large,
general population-based cohort study, we show that albu-
minuria is positively associated with tubular uric acid reab-
sorption and serum uric acid concentration. Additionally, we
observed that there is an interaction between albuminuria and
serum uric acid in their association with cardiovascular
morbidity and mortality.
Over the last decades, several studies have been published
that showed an association between albuminuria and serum
uric acid.3–7,23–28 This association has been observed in
subjects with heart failure,26 diabetes mellitus,5,6,23,28,29 and
Table 4. Association of Urinary Albumin Excretion and Serum
Uric Acid With Risk for Cardiovascular Morbidity and
Mortality, Adjusted for Cardiovascular Risk Factors
HR (95% CI) P Value
Ln albuminuria, mg/24 h per SD 1.09 (1.03 to 1.17) 0.01
Serum uric acid, mmol/L per SD 1.19 (1.09 to 1.30) <0.001
Age, y per SD 2.23 (2.00 to 2.50) <0.001
Gender, F 0.50 (0.41 to 0.61) <0.001
Use of alcohol, % 0.71 (0.60 to 0.84) <0.001
Obesity, % 1.13 (0.94 to 1.37) 0.20
History of CVD, % 1.67 (1.33 to 2.09) <0.001
Smoking, % 2.00 (1.71 to 2.34) <0.001
Diabetes mellitus, % 1.19 (0.89 to 1.59) 0.24
Hypertension, % 1.55 (1.29 to 1.86) <0.001
Hypercholesterolemia, % 1.45 (1.22 to 1.72) <0.001
eGFR, mL/min per SD 1.04 (0.95 to 1.15) 0.41
CVD indicates cardiovascular disease; eGFR, estimated glomerular ﬁltration rate (CKD
EPI-equation); HR, Hazard ratio; ln, natural log-transformed; SD, standard deviation.
Results are standardized, indicating that hazard ratios (hours) are given per standard
deviation (SD) of the variable under investigation.
Table 5. Association Between Urinary Albumin Concentration (Instead of 24 h Urinary Albumin Excretion) and Serum Uric Acid
(Dependent Variable), Crude as Well as Adjusted for Confounders
Model 1 Model 2 Model 3 Model 4
St B P Value St B P Value St B P Value St B P Value
Ln Urinary albumin concentration, mg/L 0.22 <0.001 0.11 <0.001 0.05 <0.001 0.02 0.03
Age, y 0.13 <0.001 0.11 <0.001 0.06 <0.001
Gender (female vs male) 0.51 <0.001 0.61 <0.001 0.36 <0.001
Use of alcohol (yes vs no) 0.09 <0.001 0.06 <0.001
BMI, kg/m2 0.38 <0.001 0.21 <0.001
eGFR, mL/min 0.29 <0.001 0.39 <0.001
Urinary uric acid excretion, mmol/24 h 0.02 0.03 0.43 <0.001
Tubular reabsorption of uric acid, % 0.69 <0.001
BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate (CKD EPI-equation); ln, natural log-transformed.
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hypertension,27,30 and even in subjects participating in
general population studies.3,4 Most of these studies were
cross-sectional in design. Only a limited number of studies
investigated whether a high-baseline serum uric acid predicts
development of microalbuminuria. These studies showed
contradictory results; with some describing that serum uric
acid was independently associated with de novo microalbu-
minuria. In other studies, however, this association was only
found in crude analyses, but not in analyses adjusting for
confounders. In yet another study even the crude association
was absent. Despite these contradictory longitudinal results,
the cross-sectional associations between albuminuria and
serum uric acid concentration have generally been interpreted
as uric acid causing endothelial dysfunction, which is reﬂected
by an increase in albuminuria.
In the present study we found a positive association of
albuminuria with tubular uric acid reabsorption, independent
of potential confounders a.o. hs-CRP.31 It may well be that the
expression of genes encoding for tubular uric acid transport-
ers is speciﬁcally up- or downregulated by albumin, or
nonalbumin compounds found in urine of albuminuric sub-
jects. Such a phenomenon has been observed for other, non-
urate membrane transporters in cultured tubular proximal
epithelial cells.11–14 Of note, our data suggest that nothing
much changes for tubular reabsorption of uric acid in the
upper deciles of urinary albumin excretion. This could mean
that, after a sensitive range at lower values of albuminuria,
stimulation of reabsorption or perhaps reabsorption as such is
at a maximum. Another mechanism could theoretically be that
the association we found is in fact mediated by sodium
reabsorption, since sodium depleted subjects have an
increased tubular reabsorption of sodium and at the same
time increased tubular reabsorption of uric acid.32 In our
opinion, this mechanism is less likely to play a role, because
we found that the association between albuminuria and
tubular uric acid reabsorption was independent of fractional
sodium excretion. Furthermore, it is well established that not
sodium-depleted, but on the contrary sodium-repleted sub-
jects have higher albuminuria.33 To unravel the exact
mechanism of the association that we found, dedicated, in-
depth experimental studies are necessary to investigate the
role of the various renal uric acid transporters in high
albuminuria states. Our results form a rationale to start such
research. The association of albuminuria and increased
tubular urate reabsorption may well explain the association
between albuminuria and serum uric acid concentration, as an
increased reabsorption will result in a rise in serum uric acid
concentration. The opposite, ie, an increase in serum urate
Table 6. Association Between Urinary Albumin Concentration (Instead of 24-hour Urinary Albumin Excretion) and Tubular
Reabsorption of Uric Acid (Dependent Variable), Crude as Well as Adjusted for Confounders
Model 1 Model 2 Model 3 Model 4
St B P Value St B P Value St B P Value St B P Value
Ln urinary albumin concentration, mg/L 0.24 <0.001 0.19 <0.001 0.15 <0.001 0.05 <0.001
Age, y 0.05 <0.001 0.05 <0.001 0.08 <0.001
Gender (female vs male) 0.34 <0.001 0.29 <0.001 0.35 <0.001
Use of alcohol (yes vs no) 0.01 0.22 0.05 <0.001
BMI, kg/m2 0.24 <0.001 0.25 <0.001
eGFR, mL/min 0.11 <0.001 0.14 <0.001
Urinary uric acid excretion, mmol/24 h 0.65 <0.001
ACR indicates albumin-creatinine-ratio; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate (CKD EPI-formula); ln, log-transformed.
Table 7. Associations of Urinary Albumin Concentration
(Instead of 24-hour Urinary Albumin Excretion) and Serum
Uric Acid Concentration With Cardiovascular Morbidity and
Mortality, Adjusted for Cardiovascular Risk Factors
HR (95% CI) P Value
Ln urinary albumin concentration,
mg/L per SD
1.09 (1.03 to 1.18) 0.005
Serum uric acid, mmol/L per SD 1.19 (1.09 to 1.30) <0.001
Age, y per SD 2.23 (1.99 to 2.50) <0.001
Gender (female vs male) 0.50 (0.41 to 0.61) <0.001
Use of alcohol, % 0.72 (0.61 to 0.85) <0.001
Obesity, % 1.15 (0.95 to 1.39) 0.16
History of CVD, % 1.68 (1.33 to 2.11) <0.001
Smoking, % 2.00 (1.71 to 2.34) <0.001
Diabetes mellitus, % 1.20 (0.90 to 1.61) 0.21
Hypertension, % 1.55 (1.29 to 1.86) <0.001
Hypercholesterolemia, % 1.44 (1.21 to 1.71) <0.001
eGFR, mL/min per SD 1.04 (0.94 to 1.15) 0.42
CVD indicates cardiovascular disease; eGFR, estimated glomerular ﬁltration rate (CKD
EPI-equation); ln, log-transformed; SD, standard deviation.
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concentration, will not result in an increased, but more likely a
decreased tubular urate reabsorption. We therefore, hypoth-
esize that albuminuria may be causal in the association
between albuminuria and serum uric acid concentration.
In this study, we corroborate that both albuminuria and
serum uric acid concentration are independently associated
with risk for cardiovascular morbidity and mortality.8,34 High
serum uric acid may cause endothelial dysfunction and
therefore vascular damage,8,35,36 although antioxidant prop-
erties have also been attributed to serum urate, but especially
in the lower concentration range.1,37 The mechanism by which
albuminuria is associated with cardiovascular outcome is still
unknown. In this respect only a few studies have investigated
the predictive role of both variables entered simultaneously
into a multivariable model, but these studies did not
investigate cardiovascular outcome.29,38 We found that both
variables were signiﬁcantly associated with risk for cardio-
vascular outcome, independent of traditional cardiovascular
risk factors and independent of each other. In addition, we
observed a signiﬁcant interaction between these 2 variables
in their association with cardiovascular outcome, which has
not been investigated before and may therefore have
Table 8. Association Between Urinary Albumin Excretion and Serum Uric Acid (Dependent Variable), Crude as Well as Adjusted for
Confounders, Among Which hs-CRP and Fractional Sodium Excretion
Model 1 Model 2 Model 3 Model 4
St B P Value St B P Value St B P Value St B P Value
Ln albuminuria, mg/24 h 0.23 <0.001 0.12 <0.001 0.07 <0.001 0.02 0.01
Age, y 0.12 <0.001 0.12 <0.001 0.03 0.003
Gender (female vs male) 0.51 <0.001 0.61 <0.001 0.31 <0.001
Use of alcohol (yes vs no) 0.09 <0.001 0.06 <0.001
BMI, kg/m2 0.38 <0.001 0.15 <0.001
eGFR, mL/min 0.29 <0.001 0.34 <0.001
Uric acid excretion, mmol/24 h 0.03 0.001 0.42 <0.001
Tubular reabsorption of uric acid, % 0.73 <0.001
Ln hsCRP, mg/L 0.06 <0.001
Serum albumin, g/L 0.06 <0.001
Fractional sodium excretion, % 0.14 <0.001
BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate (CKD EPI-equation); hsCRP, high sensitive CRP; ln, natural log-transformed.
Table 9. Association Between Urinary Albumin Excretion and Tubular Reabsorption of Uric Acid (Dependent Variable), Crude as
Well as Adjusted for Confounders, Among Which hs-CRP and Fractional Sodium Excretion
Model 1 Model 2 Model 3 Model 4
St B P Value St B P Value St B P Value St B P Value
Ln albuminuria, mg/24 h 0.12 <0.001 0.07 <0.001 0.03 0.01 0.05 <0.001
Age, y 0.03 0.004 0.03 0.03 0.09 <0.001
Gender (female vs male) 0.36 <0.001 0.31 <0.001 0.38 <0.001
Use of alcohol (yes vs no) 0.01 0.56 0.04 <0.001
BMI, kg/m2 0.25 <0.001 0.27 <0.001
eGFR, mL/min 0.11 <0.001 0.09 <0.001
Uric acid excretion, mmol/24 h 0.63 <0.001
Ln hsCRP, mg/L 0.04 <0.001
Serum albumin, g/L 0.06 <0.001
Fractional sodium excretion, % 0.15 <0.001
BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate (CKD EPI-equation); hsCRP, high sensitive CRP; ln, natural log-transformed.
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remained unreported to date. This latter observation suggests
that both variables are associated with outcome via a
(partially) overlapping mechanism, which ﬁts our hypothesis
that higher albuminuria may cause an increase in serum uric
acid concentration by increasing renal tubular uric acid
reabsorption. We would like to emphasize that this mecha-
nism is unlikely to be the only explanation why albuminuria is
associated with risk for cardiovascular morbidity and mortal-
ity, because albuminuria is still associated with risk even
when adjusted for serum uric acid concentration.
Our study has limitations that need to be mentioned. First,
our results are obtained in a predominantly Caucasian
population, and consequently cannot be directly extrapolated
to other ethnic groups. Second, as the intra-individual level of
urinary albumin excretion is subject to variation, eg, due to
physical activity and inﬂammatory diseases, misclassiﬁcation
may have occurred. Special care was therefore taken to
assess urinary albumin excretion as precisely as possible.
Participants were advised not to collect urine in case of fever
and to refrain from intensive physical activity during the urine
collection period. Furthermore, participants with likely errors
in their 24-hour urine sampling were excluded. Most impor-
tantly, misclassiﬁcation is expected to bias results towards
the null hypothesis (ie, no association), whereas in fact a
signiﬁcant association of albuminuria with serum uric acid
concentration and tubular uric acid reabsorption was found.
Third, our results regarding the associations of albuminuria
and tubular urate reabsorption and serum urate are obtained
in a cross-sectional analysis, which precludes ﬁrm conclu-
sions on cause-effect relationships.
Strengths of our study are that our data were obtained in a
relatively large-scale epidemiological study that was speciﬁ-
cally designed to study the course and consequences of
albuminuria. As such the PREVEND cohort is enriched for
higher levels of albuminuria, making it particularly suited for
studies investigating the association of albuminuria with other
variables. Of note, even when adjusted for study design
essentially similar results were obtained, making our data
robust. Furthermore, albuminuria was assessed immediately
in 2 fresh 24-hour urine collections, whereas in most
epidemiological studies albuminuria is assessed in 1 random
spot-urine sample after prolonged frozen storage, which is
known to be subject to more variability.39,40 Lastly, in our
participants extensive information is available on a large
number of covariates, including medication use, which allows
adjustment for confounders in multivariable analyses.
In conclusion, our study showed a strong association
between albuminuria and uric acid reabsorption. This rela-
tionship could be due to albuminuria enhancing proximal
tubular urate reabsorption. Controlling for serum uric acid
levels strongly decreased the predictive value of albuminuria
with regard to cardiovascular events. This phenomenon may
explain in part why albuminuria is associated with cardiovas-
cular outcome.
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